Navigation Links
SCOLR Pharma, Inc. Reports Third Quarter 2010 Financial Results
Date:11/10/2010

BOTHELL, Wash., Nov. 10, 2010 /PRNewswire-FirstCall/ -- SCOLR Pharma, Inc. (NYSE AMEX: DDD) today reported financial results for the three and nine months ended September 30, 2010.Stephen J. Turner, SCOLR Pharma's President and CEO, said, "Our focus for the remainder of the year will be to continue executing the plans for our extended release nutritional supplement and drug delivery businesses, which have both been advanced in the last quarter.

"We believe that our extended release formulations of nutritional products will offer consumers the benefits of these supplements on a continuous basis throughout the day, while also providing retailers an opportunity to provide their customers with greater choice.  Working with the Emerson Group, we have been meeting with national retailers during their fourth quarter 2010 purchase planning cycles to present our nutritional products.  Orders placed by these retailers in late 2010 or early 2011 would be expected to ship in early-mid 2011," Turner added.

Turner continued:  "In the drug delivery business, we appear to be in the final stages of review by the Food and Drug Administration of our Abbreviated New Drug Application for extended release pseudoephedrine.  Additionally, we have nearly completed protocol planning for the actual use label comprehension study for our extended release, 12-hour ibuprofen product.  We expect to engage a services provider in the first quarter of 2011 in preparation for the conduct of that study. Additional revenue, financing or partnership support is required to complete the study, but we believe the Company is well positioned to move forward."

SCOLR Pharma also announced it was recently engaged by RedHill BioPharma, Ltd., to develop and test the manufacturing feasibility of prototype ondansetron tablets incorporating SCOLR's CDT technology. RedHill is an Isr
'/>"/>

SOURCE SCOLR Pharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. SCOLR Pharma, Inc. Names Carl Johnson as Chairman; Former Chairman Michael Taglich Remains as Director
2. SCOLR Pharma, Inc. Signs Agreement with The Emerson Group to Provide Sales Support for Nutritional & OTC Products
3. SCOLR Pharma, Inc. Enters into Worldwide Licensing Agreement with RedHill Biopharma Ltd.
4. SCOLR Pharma, Inc. Licenses Dietary Supplements
5. SCOLR Pharma, Inc. Receives Notices From NYSE Amex LLC Regarding Compliance Plan and Listing Standards
6. SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results
7. SCOLR Pharma, Inc. Reports Third Quarter 2008 Financial Results
8. SCOLR Pharma Announces Completion of Patient Enrollment and Dosing for Pivotal Clinical Trial Evaluating Extended Release Ibuprofen
9. Reportlinker Adds Merger and Acquisition Terms and Agreements in Pharma, Biotech and Diagnostics, 4th edition
10. Reportlinker Adds Co-promotion and Co-marketing Agreements in Pharma, Biotech and Diagnostics, 4th Edition
11. Horizon Pharma, Inc. Files Registration Statement for Proposed Initial Public Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... , March 5, 2015 Vermillion, ... solutions company focused on gynecologic disease, announced today ... results before the market open on Wednesday, March ... and webcast at 8:30am Eastern. Conference Call & ... at 8:30am Eastern/5:30am Pacific Domestic: , 800-753-9057International: , ...
(Date:3/5/2015)... Germany , March 5, 2015 ... today announced that the foundation has made a ... CureVac, a leading clinical-stage biopharmaceutical company specializing in ... the foundation will also provide separate funding for ... CureVac,s proprietary messenger RNA (mRNA) platform. In addition, ...
(Date:3/5/2015)... 5, 2015 Bayer HealthCare announced today that ... Cancer Foundation of the American Society of Clinical Oncology ... technology platform designed to unlock vast quantities of information ... "Bayer is proud to join ASCO and ... Big Data to help people whose lives have been ...
Breaking Medicine Technology:Vermillion to Report Fourth Quarter and Year-End 2014 Financial Results and Host an Investor Conference Call on March 25 2The Bill & Melinda Gates Foundation and CureVac Collaborate to Accelerate the Development of Transformative Vaccine Technology 2The Bill & Melinda Gates Foundation and CureVac Collaborate to Accelerate the Development of Transformative Vaccine Technology 3The Bill & Melinda Gates Foundation and CureVac Collaborate to Accelerate the Development of Transformative Vaccine Technology 4Bayer HealthCare Contributes $1 Million to Support Cancer Care Technology Platform 2Bayer HealthCare Contributes $1 Million to Support Cancer Care Technology Platform 3
... that a new market research report is available in ... http://www.reportlinker.com/p0324751/Toxicology-and-Pharmacology.html Toxicology ... Economic Challenges – key report at new low price ... and the market is worth nearly $3 billion. But ...
... 2010 Pfizer Inc. (NYSE: PFE ) ... listen to a webcast of a presentation by Olivier ... 2010 Annual Credit Suisse Healthcare Conference on Wednesday, November ... (Logo: http://photos.prnewswire.com/prnh/20100416/PFIZERLOGO) (Logo: http://www.newscom.com/cgi-bin/prnh/20100416/PFIZERLOGO) ...
Cached Medicine Technology:Reportlinker Adds Toxicology and Pharmacology 2Reportlinker Adds Toxicology and Pharmacology 3
(Date:3/6/2015)... TN (PRWEB) March 06, 2015 Since ... January 1, 2015, there has been an overwhelming demand ... an efficient and compliant CCM program. The Centers ... on several matters. , PYA’s updated white paper—“ ... this new guidance into a detailed, yet practical “how ...
(Date:3/6/2015)... 06, 2015 Many patients with knee ... therapy. If you (or someone you know) have chronic ... you may be interested in the ACT-OA clinical trial. ... today that he is one of fifteen physicians in ... begin enrolling subjects as part of a new, multi-site, ...
(Date:3/6/2015)... (PRWEB) March 06, 2015 Magellan Rx ... only comprehensive source for key trends and statistics on ... medical injectables. Executives from Magellan Rx Management will discuss ... Report: Discover Your Hidden Specialty Drug Spend,” a complimentary ... Services, Inc. , Specialty drug spend makes up more ...
(Date:3/6/2015)... (PRWEB) March 06, 2015 Utilizing the ... and rapidly reach their ideal weight has enabled Diet ... to their already impressive collection of fat loss ... existing clients special promotions and savings to help people ... immediately. This promotion is especially appealing to new ...
(Date:3/6/2015)... Yisrayl Hawkins, Pastor and Overseer of The House ... publication explaining how micro-kingdoms keep the earth and everything ... “Microorganisms Do Much More Than You Think” is a ... and designed to keep all things functioning properly. He ... of these micro-kingdom, but does not realize their full ...
Breaking Medicine News(10 mins):Health News:Updated PYA White Paper Meets Demand for Guidance on Providing and Billing Medicare for Chronic Care Management 2Health News:Kevin Darr, M.D. is Now Enrolling Patients in a New FDA-Approved Clinical Trial Evaluating Adipose-Derived Regenerative Cells in the Treatment of Knee Osteoarthritis 2Health News:Atlantic Information Services, Magellan Rx Management Partner on Complimentary Webinar Outlining Key Findings of New Medical Pharmacy Trend Report 2Health News:Diet Doc Announces Never Before Offered Discounts, Promotions and Savings for New and Existing Clients 2Health News:Diet Doc Announces Never Before Offered Discounts, Promotions and Savings for New and Existing Clients 3Health News:Diet Doc Announces Never Before Offered Discounts, Promotions and Savings for New and Existing Clients 4Health News:Yisrayl Hawkins Tells Scientists Exactly What Makes Life Function Properly in New Publication 2
... of fetuin-A were linked to later disease development, study ... Rising levels of a blood protein called fetuin-A may ... new research suggests. , Reporting in the current issue ... , researchers from the University of California, San Diego, ...
... HumanWare expands its low vision,product line with the announcement ... conference on low vision being held in Montreal this,week. ... serve the needs,of the growing number of people with ... even with the most powerful prescription glasses., HumanWare,s ...
... keeps muscles from getting too big may optimize recovery of ... inhibitors in mice with limb injuries, first to see which ... says Dr. Mark Hamrick, bone biologist in the Medical College ... "Fifty to 60 percent of the injuries occurring in Iraq ...
... Young to expand sales efforts for nationwide managed care ... a wholly,owned subsidiary of GAB Robins North America, Inc., ... Young has joined its sales,team as vice president of ... great asset to MedInsights as we expand our national,sales ...
... Need for Parents to Include Life Insurance ... in Their College-Funding Plans, ARLINGTON, ... -- turns. When a loved one dies, it can be particularly,painful. ... that comes when the head of the household dies,prematurely with little ...
... is a,statement by Matthew L. Myers, President, Campaign for ... taken important action to,protect public health by proposing to ... ratings are based on an,FTC-approved testing method or that ... warns tobacco companies that they risk legal action by,the ...
Cached Medicine News:Health News:A Blood Marker Could Spot Diabetes Risk 2Health News:A Blood Marker Could Spot Diabetes Risk 3Health News:HumanWare introduces four new portable video magnifiers for low vision 2Health News:Myostatin inhibitors may improve recovery of wartime limb injuries 2Health News:Myostatin inhibitors may improve recovery of wartime limb injuries 3Health News:MedInsights, Inc. Selects Douglas Young as VP - Sales & Product Development 2Health News:LIFE Foundation Asks Public to Vote to Determine its $5,000 Life Lessons College Scholarship Winner 2Health News:LIFE Foundation Asks Public to Vote to Determine its $5,000 Life Lessons College Scholarship Winner 3Health News:FTC Acts to Prevent Tobacco Industry Deception About Tar, Nicotine Levels; Congress Should Go Further by Giving FDA Authority Over Tobacco Products 2Health News:FTC Acts to Prevent Tobacco Industry Deception About Tar, Nicotine Levels; Congress Should Go Further by Giving FDA Authority Over Tobacco Products 3
... device for the qualitative detection of drug or ... device can detect up to nine of the ... minutes and requires only a few drops of ... maximize convenience and ease of use. TOX/See features ...
... 1-step, hand-held, point-of-care device for the qualitative detection ... The TOX/See device can detect up to ... 3 to 8 minutes and requires only a ... individually packaged to maximize convenience and ease of ...
... TOX/See™ is a 1-step, hand-held, point-of-care device for ... in human urine. The TOX/See device can ... abused drugs in 3 to 8 minutes and ... TOX/See cassette is individually packaged to maximize convenience ...
... Solution offers relief from CTS pain and ... from other over-the-counter CTS treatments. It is ... sleep, the Carpal Solution gently reshapes soft ... and eliminates hand pain, numbness and sleep ...
Medicine Products: